Member Info for Bothwell

https://mol.im/a/10707513

From July 2021

PRO finished, discussions ongoing with FDA, protocol power size calculated (given magnitude of effect, other phase III studies and real world experience doesn’t have to be large) sites identified, drug supply available, data now in Hispanics and African Americans, market size analysis and price point sensitivity re-done by top tier US marketing organisation, licensing partners have access to data room and have been updated. Play out over the next 12-18 months.

https://www.nature.com/articles/s41443-022-00554-8

Fortacin selling for £72 on Alliance Healthcare. CT FORTACIN 150MG/ML 5ML

Only interested in USA and China now. Not far away.

We are only concerned about USA and China. Europe will come back round once we have been approved in both of these areas . All under control with Jim and Jamie.

Within the next year.

This is no write off. It is a long waiting game where we will have USA approval and success.

Hope for an upturn in our fortunes. Been a long wait… FDA approval is all I require!

Could 2022 be our year…… We all deserve it as we have waited far too long.

I was informed a while ago within the next 18 months.

Totally agree bignose. We have stayed this long, not long to wait now…….

Really hope we are not too far away now……from success. It been a long road.

Same here!

Deltex Medical Group plc (AIM:DEMG) is in demand after it won a key order for its monitors.

The company, whose technology is used in critical care and general surgical procedures, said it had received a US$200,000 order from a distributor in the Americas for its TrueVue monitors.

The two have been working for 18 months to gain approval for the monitors, which measure blood flow velocity in the central circulation in real time.

Initially the distributor purchased five monitors to carry out in-hospital evaluations and these trials proved successful leading to the TrueVue technology being chosen to fulfil an initial government tender in that market.

As a result, Deltex has now received an initial order for monitors to fulfil government-awarded contracts, with installation expected over the next nine months. Further monitor orders are expected later this year once more tenders are awarded.

The order will also result in contracted monthly revenues for the single-use probes, which are used with these devices.

Once we get both then we will head to 70 and beyond.

All I am waiting for is approval in USA and China. It has been a number of years in the waiting…….

Surely our product is better than this one.

Interesting day. 2,5 volume and up 13%.

As at 13 December 2021, the Company’s investment in DVP (formerly known as Venturex Resources Limited) shares and DVP options have increased significantly to approximately US$12.74 million (or approximately HK$99.37 million) from 31 December 2020. The Company’s current fair value gain of its holding of DVP shares and DVP options together with the subscriptions and disposals of certain DVP shares during the year is approximately US$14.88 million (or approximately HK$116.06 million), representing an increase of approximately (((622.59%))) from 31 December 2020. The fair value gain for the financial year ending 31 December 2021 is subject to change based on DVP’s share price as at 31 December 2021.

Break even is a good bit off for me! Then again I still hope to more than double my initial stake here when we succeed in the USofA!